Unknown Author
January 23, 2026
Sidley Represented Resolian in its Acquisition of China-Based Bioanalytical CRO Denali Medpharma

2 min
AI-made summary
- Sidley advised Resolian, a global bioanalytical contract research organization specializing in drug metabolism and pharmacokinetics, on its acquisition of Denali Medpharma, a leading China-based bioanalytical CRO
- Resolian operates bioanalysis laboratories in the U.S., UK, Australia, and China
- The transaction was managed by a multidisciplinary, cross-border Sidley team led by partner Ruchun Ji, with involvement from corporate, regulatory, tax, and antitrust practice areas.
Sidley represented Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, in the acquisition of Denali Medpharma, a leading China-based bioanalytical CRO. Resolian has bioanalysis laboratory operations in the U.S., UK, Australia, and China. The multidisciplinary Sidley team was led by partner Ruchun Ji. The transaction involved a cross-border team working across several practice areas, including the following: Corporate and M&A: partner Ruchun Ji, senior managing associate Jing Peng and counsel Ling Chen; Regulatory: senior counsel Chen Yang and senior managing associate Mulai Xu; Tax: partner Oliver Currall; and Antitrust: partner Patrick Harrison, and associates Iva Todorova and Fiona Shajko. Sidley’s Global Life Sciences practice, which comprises more than 200 dedicated lawyers globally, offers cross-disciplinary, full-service solutions for life science clients, ranging from M&A and private equity, licensing and collaboration transactions, capital markets, regulatory compliance and enforcement, and dispute resolutions, assisting biotech and pharmaceutical clients around the world. Sidley’s China Life Sciences practice, an integral part of the firm’s Global Life Sciences practice, is the only Band One international firm ranked by Chambers Asia Pacific/Greater China Region for 14 consecutive years.~~Sidley represented Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, in the acquisition of Denali Medpharma, a leading China-based bioanalytical CRO. Resolian has bioanalysis laboratory operations in the U.S., UK, Australia, and China. The multidisciplinary Sidley team was led by partner Ruchun Ji. The transaction involved a cross-border team working across several practice areas, including the following: Corporate and M&A: partner Ruchun Ji, senior managing associate Jing Peng and counsel Ling Chen; Regulatory: senior counsel Chen Yang and senior managing associate Mulai Xu; Tax: partner Oliver Currall; and Antitrust: partner Patrick Harrison, and associates Iva Todorova and Fiona Shajko. Sidley’s Global Life Sciences practice, which comprises more than 200 dedicated lawyers globally, offers cross-disciplinary, full-service solutions for life science clients, ranging from M&A and private equity, licensing and collaboration transactions, capital markets, regulatory compliance and enforcement, and dispute resolutions, assisting biotech and pharmaceutical clients around the world. Sidley’s China Life Sciences practice, an integral part of the firm’s Global Life Sciences practice, is the only Band One international firm ranked by Chambers Asia Pacific/Greater China Region for 14 consecutive years.
Article Author
Unknown Author
The Sponsor
